The cancer, autoimmune and rare disease drug developer completed a $65m round that also featured MRL Ventures Fund and Cleva Pharma.

Pharmaceutical firm GlaxoSmithKline (GSK) has led a $65m series B round for US-based small molecule drug developer HotSpot Therapeutics through its corporate venture capital unit, SR One.

The round included MRL Ventures Fund, a corporate VC vehicle for pharmaceutical firm Merck & Co, and Cleva Pharma, an affiliate of pharmaceutical company EMS’s Brace Pharma subsidiary.

Atlas Venture and Sofinnova Partners filled out the round alongside Aju IB Investment’s Solasta Ventures subsidiary and funds managed by Tekla Capital Management. It came…

Robert Lavine

Robert Lavine is special features editor for Global Venturing.